Kofasma syrup 100ml vials

Description

Composition
Active substance:
10 ml of syrup contains:
Salbutamol is salbutamol sulfate equivalent to 2.0 mg;
Bromhexine hydrochloride, 4.0 mg;
Guaifenesin 100,0mg.
Excipients:
levomenthol – 1.0 mg, propylene glycol – 2050.0 mg Aspartame – 60.0 mg Sodium benzoate – 20.0 mg Citric acid – 40.0 mg Sodium Citrate dihydrate – 22.8 mg, sunset yellow dye – 0.15 mg, pineapple flavor – 0.01 mL, hypromellose – 70.0 mg purified water – up to 10 ml.
Description:
Expectorant combination.
Product form:
Syrup.
100 ml or 200 ml of the product in a plastic bottle with screw dark colored aluminum lid with tamper-evident.
Contraindications
phenylketonuria; tachyarrhythmia; myocarditis; tachycardia; heart diseases (including aortic stenosis); decompensated diabetes; hyperthyroidism; glaucoma; liver and / or renal failure; gastric ulcer and duodenum 12 (in the acute phase); gastric bleeding; pregnancy;
lactation; hypersensitivity to the drug.
Carefully.
With care prescribe a drug to patients with hyperthyroidism, diabetes, severe diseases of the cardiovascular system, hypertension, gastric ulcer and duodenal ulcer in remission. Should not be used Kofasma in combination with beta-blockers.
Dosage
2 mg + 50 mg + 1 mg / 5 ml
Indications
In the combined therapy of acute and chronic bronchopulmonary diseases accompanied by formation of difficult to separate viscous secretion:
-bronchial asthma;
-ostry and chronic bronchitis;
-emfizema lungs;
-hronicheskaya obstructive pulmonary disease;
-traheobronhit;
-pneumonia;
-pnevmokonioz;
-pulmonary tuberculosis;
-whooping cough.
Interaction with other drugs
With simultaneous use of beta-agonists and theophylline, and others. Ksanatiny increase the likelihood of tachyarrhythmias.
Not recommended for use with monoamine oxidase inhibitors and tricyclic antidepressants, since they enhance the effect of salbutamol, may lead to a sharp decrease in blood pressure.
Incompatible with nonselective beta-blockers. Diuretics and steroids increase hypokalemic effect of salbutamol.
Not administered with preparations containing codeine and others. Antitussives (difficult expectoration).
Part of the preparation bromhexine promotes penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) in pulmonary tissue.
Overdose
Symptoms may increase manifestations described side effects.
Treatment: symptomatic therapy if necessary.
pharmachologic effect
Pharmacological properties:
Combined preparation has a bronchodilator, an expectorant and mucolytic action.
Salbutamol – bronchodilator stimulate beta-2 adrenergic receptors bronchi, blood vessels and myometrium. Prevents or eliminates bronchospasm, reducing airway resistance increases vital capacity (VC). Causes expansion of the coronary arteries, does not lower blood pressure (BP).
Bromhexinum – mucolytic agent has expectorant action. Increases serous components bronchial secretions; cilia activates the ciliated epithelium, lowers the viscosity of sputum, its volume increases and improves expectoration.
Guaifenesin – mucolytic agent reduces the surface tension structures bronchopulmonary apparatus; stimulates secretory bronchial mucosa cells that produce neutral polysaccharides depolymerized-acidic mucopolysaccharides, reduces the viscosity of sputum, bronchial activates ciliary apparatus, facilitates the removal of sputum and facilitates the transition nonproductive cough productive.
Pharmacokinetics:
Salbutamol.
Absorption and distribution: After oral administration, absorption is high. The bioavailability of ingested salbutamol is about 50%. Food intake reduces the rate of absorption, but does not affect the bioavailability.
Relationship to plasma proteins – 10%. It crosses the placental barrier.
Metabolism and excretion: is subjected to first-pass metabolism in the liver and in the intestinal wall,
fenolsulfotransferazy inactivated by up to 4-O-sulfate ester. The half-life (T1 / 2) -. 3.8-6 hours is derived from urine (69-90%), preferably in the form of inactive metabolite phenol sulphate (60%) for 72 hours and in the bile (4%).
Bromhexine.
Absorption and distribution: ingestion almost completely (99%) absorbed in the gastrointestinal
tract for 30 min. Bioavailability is low (the “first pass” through the liver). It crosses the placental barrier and the blood-brain barrier (BBB).
Metabolism and excretion: in liver undergoes demethylation and oxidation, is metabolised to pharmacologists cally active ambroxol. T1 / 2 -15 hr (due to slow reverse diffusion from the tissue). Excreted by the kidneys. In chronic renal failure disturbed the excretion of metabolites. Repeated application may accumulate.
Guaifenesin.
Absorption and distribution: absorption from the gastrointestinal tract fast (25-30 minutes after ingestion). Into the tissue containing acidic mucopolysaccharides.
Metabolism and excretion: approximately 60% of the administered drug is metabolized in the liver.
T 1/2 – 1 hour. Deduced lungs (sputum) and kidneys in unchanged form and as inactive metabolites.
Pregnancy and breast-feeding
Contraindicated the use of this drug during pregnancy and lactation.
Conditions of supply of pharmacies
On prescription.
side effects
On the part of the central nervous system: tremor, muscle cramps. When used in high doses – headache, dizziness, irritability, sleep disturbance, drowsiness.
On the part of the gastrointestinal tract: nausea, vomiting, diarrhea, exacerbation of gastric ulcer and duodenal ulcer 1.2, increased activity of “liver” transaminases.
Cardio-vascular system: tachycardia, decreased blood pressure, peripheral vasodilatation, collapse.
From the urinary system: urine staining pink color. Allergic reactions :, skin rash, urticaria, paradoxical bronchospasm.
special instructions
Guaifenesin urine stains pink. It is not recommended to take the drug at the same time alkaline drinking.
Effects on ability to drive and engage in other potentially hazardous activities.
Given the profile of side effects (dizziness, drowsiness etc.) is recommended during treatment to refrain from driving, lessons from other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store in a tightly closed vial at a temperature not higher than 25 ° C. Do not freeze.
Keep out of the reach of children.
Dosing and Administration
Inside, adults and children over 12 years of 10 ml (2 teaspoons) 3 times / day.
Children under the age of 6 – 5 ml (1 teaspoon) 3 times / day.
Children 6 to 12 years – 5-10 ml (1-2 teaspoons) 3 times / day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist